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Abstract
Background: We have examined the genomic distribution of large rare autosomal deletions in a sample of 440 parent-
parent-child trios from the Quebec founder population (QFP) which was recruited for a study of Attention Deficit
Hyperactivity Disorder.
Methodology/Principal Findings: DNA isolated from blood was genotyped on Illumina Hap300 arrays. PennCNV combined
with visual evaluation of images generated by the Beadstudio program was used to determine deletion boundary definition
of sufficient precision to discern independent events, with near-perfect concordance between parent and child in about
98% of the 399 events detected in the offspring; the remaining 7 deletions were considered de novo. We defined several
genomic regions of very high deletion frequency (‘hotspots’), usually of 0.4–0.6 Mb in length where independent rare
deletions were found at frequencies of up to 100 fold higher than the average for the genome as a whole. Five of the 7 de
novo deletions were in these hotspots. The same hotspots were also observed in three other studies on members of the
QFP, those with schizophrenia, with endometriosis and those from a longevity cohort.
Conclusions/Significance: Nine of the 13 hotspots carry one gene (7 of which are very long), while the rest contain no
known genes. All nine genes have been implicated in disease. The patterns of exon deletions support the proposed roles for
some of these genes in human disease, such as NRXN1 and PARKIN, and suggest limited roles or no role at all, for others,
including MACROD2 and CTNNA3. Our results also offer an alternative interpretation for the observations of deletions in
tumors which have been proposed as reflecting tumor-suppressive activity of genes in these hotspots.
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Introduction
Recent improvements in microarray-based genotyping technol-
ogy have led to significant advances in our understanding of the
genetic contribution to common disease in the last few years. In
addition to identification of chromosome regions carrying haplo-
types putatively involved in conferring disease susceptibility, these
studies have also allowed quantitative assessment of large-scale
deletions and duplications (also known as copy number varia-
tions, CNVs) on a genome-wide basis. The number of individuals
carrying a given CNV at a known gene locus is frequently small, so
conventional association studies based on statistical analyses cannot
always be performed. Nevertheless, discovery of these anecdotal
changes can be useful since, for example, deletion of even a portion
of one copy of a gene expected to have an important biological role
can have important consequences and can ultimately lead to
insights into disease etiology.
A number of publications have documented copy number
variations (CNV) in a variety of population samples using data
from genome-wide association studies. These contributions have
revealed potentially important roles for CNVs in disorders such as
autism, schizophrenia and other neurological conditions [1]–[4].
In particular, a recurring observation is that of deletions in the
very large neurexin-1 gene, and to these findings can be added the
description of chromosomal rearrangements in or near the NRXN1
locus in two subjects with autism spectrum disorder [5],[6].
Whether these changes are indeed contributory to disease,
however, has been questioned in a report of a large autism study
in which segregation of the deletions with disease was not observed
in 4 of 6 families [7]. Resolution of this issue would be very
instructive, as the gene in question is an important component of
synapse complexes.
Genizon Biosciences has recently used the Illumina Infinium
Hap300 platform to complete genome-wide studies of 550 atten-
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osis (EN) simplex patients and 480 schizophrenia (SZ) simplex
patients, as well as 640 recruited in a longevity study (LG; this
sample comprised individuals more than 95 years of age and was
genotyped on the Illumina Hap550 array). As a first step in
determining the possible role of rare autosomal deletions in our
samples, we evaluated fluorescence intensities as presented by the
Beadstudio program, using a combination of computer-based
scanning and individual assessment by human observer. The trio
structure of the ADHD study allowed mutual verification of each
transmitted deletion in both parent and child, and we were able
precisely to define those SNPs situated within each deletion. We
found remarkable patterns of clustering, with variation in fre-
quency of independent deletion events per unit length of as much
as 100-fold across the genome. The points of greatest deletion
frequency fell within about 15 regions mostly of about 0.4–0.6 Mb
in length; 13 of these were evaluated in the other cohorts and
found to be similarly enriched for deletions. Four of the regions
had no genes whereas nine harbored a single gene or gene region,
all nine of which have been implicated in disease. The patterns
of exon loss vs. retention allowed insights into the role, or lack
thereof, of the genes in the respective diseases.
Results
The number of transmitted and non-transmitted autosomal
deletions in the ADHD trios: The analysis of the offspring as
described in the Methods and in the Supporting Information S1
resulted in 343 rare, independent candidate deletions in 440 cases
which were called by PennCNV and supported by visual
inspection. These are referred to as affirmed deletions. 23 of these
were also present in a second individual for a total of 366. Of
these, 274 had the same deletion called by PennCNV in one or the
other parent. Visual inspection of the corresponding Beadstudio
images showed that 85 of the remaining 92 were false negatives, in
that identical deletions were clearly demonstrable in one of the
parents. A total of 359 transmitted deletions (336 independent)
were therefore found in this round, and we conclude that 7 of the
affirmed calls were de novo deletions.
In the second round we examined the deletions called by
PennCNV in the parents, and found 549 independent rare
deletions which were visually affirmed, of which 49 were present in
a second parental sample for a total of 598. Of these 598, 270 had
called, affirmed deletions in their offspring from the first round.
The samples of the offspring of each of the other 328 parents were
visually examined in the Beadstudio application for any uncalled
deletions corresponding to that found in the parent. Thirty-three
were found, of which 6 had already been found in other trios.
(Possible reasons for the lower rate of apparent false negatives in
the second round are discussed in Supporting Information S1.)
This iterative process therefore revealed a total of 399 deletions,
counting the de novo events, in offspring for both rounds of in-
spection. 368 were independent (listed in the first table of
Supporting Information S1), and since we calculate the sensitivity
of this process to be about 0.94 (see Supporting Information S1),
they probably represent nearly all of the deletions in the offspr-
ing that are detectable with this approach. Among the non-
transmitted chromosomes we detected 270 different affirmed
deletions, of which 20 were present in a second non-transmitted
chromosome, for a total of 291 detected in all non-transmitted
chromosomes. This number is almost certainly less than the real
number, since the sensitivity of PennCNV without the benefit of
the 2-generation cross-verification is estimated at about 0.75 (see
Supporting Information S1). Indeed, the respective calculated
sensitivities suggest that the numbers in the transmitted and non-
transmitted chromosomes were not significantly different, at about
390 and 360 respectively.
Distribution of the deletions in the genome: A striking obser-
vation is that many of the deletions cluster within a limited number
of chromosomal regions. Examples are shown in Fig. 1A, which
illustrates the results for all of chromosome 20 on which two
clusters were found. Of the total of 16 transmitted and 3 de novo
deletions found in the 440 ADHD patients, all of the de novo and 5
of the transmitted deletions were located between 14.5 and
15.0 Mb, and a further 4 transmitted deletions were found in
another region at approximately 40.5–40.7 Mb. Fig. 1B shows the
first 25 Mb of chromosome 9, carrying a cluster of 5 deletions in
band 9p23. (Note there is one large deletion immediately before
this cluster which could arguably be considered as being within the
region.)
Similar deviation from uniform distribution was seen in several
other regions, which generally ranged from 0.4–0.6 Mb in length
(Table 1). For purposes of calculation and discussion, we choose
the unit length of these regions, which we refer to as ‘hotspots’, to
be 0.6 Mb, since some of the apparently shorter domains, such as
that at 40.5–40.7 Mb on Chr20, may in fact be longer than shown
in Table 1 simply because not enough deletions have been found
to represent the full length of the region. A Poisson distribution
analysis (Supporting Information S1) revealed that, assuming no
bias in distribution of deletions, the number of 0.6 Mb chromo-
some segments carrying 2, 3, and 4 independent rare trans-
mitted or de novo deletions is expected to be 14, 0.38 and 0.008,
respectively, whereas the numbers actually found were 33, 6 and 5.
The two domains with 5 and 8 deletions were even further
removed from the pattern predicted by the Poisson equation if no
bias existed, with about 10
24 and 10
210 expected, respectively.
We can therefore state with confidence that virtually all 13
domains with 3 or more deletions were unexpectedly ‘hot’. Fur-
thermore, since 19 more domains than expected were found in
which two deletions resided, we interpret the results as suggesting
that the real number of hotspots may be of the order of 30 or
more. This in fact represents a minimum, since we have no way of
knowing how many hotspots may exist for which a deletion is
lethal, or results in a phenotype excluded by our recruiting criteria.
(This is illustrated by data presented below, where we find, as have
others, that the hotspot in 2p16.3 is preferentially deleted in SZ
patients
The genomic distribution of deletions in the non-transmitted
chromosomes was then examined and again these were found to
cluster in hotspot regions. Eight of the 11 loci in the ‘transmitted’
list of hotspots were also in the list of non-transmitted deletion
hotspots, and only one locus (chr16p13.2) with no transmitted
deletions was represented on the non-transmitted list of hotspots
(Table 1). On the other hand, those deletions in the bulk of the
genome (‘non-hotspot deletions’) were distributed in an apparently
random fashion. The average enrichment for deletions per unit
length of DNA in the hotspots was about 50-fold in both
transmitted and non-transmitted chromosomes (Table 1), rising to
more than 100-fold in the most extreme cases of 9p23 and 20p12.
To determine the universality of these hotspot domains, 13 of
the domains with three or more deletions in the entire ADHD
study were assessed for deletions present in other samples. The
PennCNV algorithm was used to identify candidate deletions
within Genizon’s SZ and EN samples, and subsequently the visual
inspection protocol developed for ADHD was used to confirm
these loci (Supporting Information S1). Whereas the overall
density of affirmed non-hotspot deletions was about the same in
the other cohorts as for ADHD (with the exception of SZ which
High Frequency Deletions
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Number of independent deletions found (number of deletions affecting coding exons)
ADHD EN SZ LG
Region location
Limits of region
(Mb) Gene Trans-mitted* non-transmitted
Independent in all
chromosomes
1q43 235.2–235.7 none 4 (na) 0 (na) 4 1 (na) 1 (na) 1 (na)
2p16.3 50.7–51.3 NRXN1 2 (1) 1 (0) 3 2 (0) 7 (2) 3 (0)
6q26 162.5–162.9 PARKIN 4 (2) 5 (4) 9 1 (0) 3 (2) 6 (1)
8p23.2 4.3–4.9 CSMD1 3 (0) 1 (0) 3 3 (0) 2 (0) 3 (0)
8p23.2 5.6–6.2 none 2 (na) 2 (na) 4 3 (na) 3 (na) 1 (na)
8p22 15.2–15.6 TUSC3 4 (1) 1 (0) 5 0 (0) 0 (0) 1 (0)
9p23 11.7–12.2 none 5 (na) 5 (na) 9 7 (na) 8 (na) 13 (na)
9p21.1 30.4–30.7 none 3 (na) 0 (na) 3 1 (na) 3 (na) 1 (na)
10q21.3 67.8–68.2 CTNNA3 3 (3) 5 (4) 7 8 (4) 4 (2) 8 (4)
13q31.1 83.1–83.7 SLITRK1 4 (0) 4 (0) 8 2 (0) 2 (0) 3 (0)
16p13.2 6.6–7.0 A2BP1 0 (0) 4 (0) 4 1 (0) 4 (1) 4 (1)
20p12.1 14.5–15.1 MACROD2 8 (0) 4 (0) 11 9 (3) 6 (0) 3 (0)
20q12 40.5–40.7 PTPRT 4(0) 0 (0) 4 2 (0) 0 (0) 1 (0)
ADHD, attention deficit hyperactivity disorder, 440 parent-parent trios; EN, 540 endometriosis simplex patients; SZ, 480 schizophrenia simplex patients; LG, 640
individuals over 95 years of age.
*includes 4 de novo deletions, three in 20p12.1 and one in 2p16.3.
doi:10.1371/journal.pone.0009401.t001
Figure 1. Distribution of transmitted and de novo deletions in the ADHD sample of 440 parent-parent trios. Two regions with
particularly high frequency of deletions are presented, using the UCSC Genome Browser. A. Chromosome 20. The hotspot in 20p12 was the most
unstable, with 27 independent deletions in four population samples comprising 2540 individuals. A second hotspot was observed on this
chromosome, at about 40.6 Mb. B. First 25 Mb of Chromosome 9. No de novo deletions were documented in this chromosome.
doi:10.1371/journal.pone.0009401.g001
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observed clustering in the same regions as in the ADHD trios,
indicating that the clustering effect was not limited to this cohort
(Table 1).
A third sample for longevity, which had been genotyped with
the Illumina 550k microarray was analyzed separately and again,
clustering was observed within the same hotspots (Table 1).
Characteristics of the Deletions and the Hotspots
The mean length of the 135 different clustered deletions which
were found in all samples was 94 kb, very close to the mean for the
non-HS transmitted ADHD deletions, but the median was 54 kb,
nearly twice that of the latter. The standard deviation was much
greater in the latter group, (219 kb vs. 111 kb). These numbers
reflect a greater uniformity in length in deletions found in hotspots,
with 68% being between 20 and 200 kb, compared with 50.2% for
non-HS deletions (chi square 4.01, p,0.05) falling within this size
range. This length corresponds very approximately with the length
of chromatin loops, and may reflect some aspect of the mechanism
for this high frequency deletion phenomenon.
We were able to trace the parent-of-origin for five of the de novo
deletions, being the hotspot deletions in 2p16.3, 6q26 and 20p12.1.
In three of the five, the deletion was maternally inherited, a ratio
similar to that found in the major hotspot in the DMD gene (P.
Helderman and E. Bakker, personal communication).
With respect to gene content, a remarkable characteristic of the
hotspots is the length of the genes therein. Nine of the domains
have one and only one gene, and 7 of them rank among the 35
longest genes in the genome (according to gene annotations in the
UCSC Genome Browser), including 4 in the top 8. The regions of
greatest deletion frequency are in the regions of very long introns
in the long genes, usually the 59 end. Interestingly, the DMD
hotspot extending from exon 44 to exon 53 which is comparable to
those described here is in the longest gene. In any event, it is
clear that the coding sequence density is, on average, very low in
the hotspots. As noted below, none of the sequence motifs, or
functional entities known or suspected to be involved in chro-
mosomal instability are present in abundance in any of the hot-
spots. Furthermore, the proximity of fragile sites, which overlap
with only one of the 13 regions we identify (6q26), does not explain
the major part of this instability.
Discussion
We have documented the presence of 13 regions of about
0.5 Mb each in the human genome where deletions occur at up to
100-fold higher frequency than the other 99.8% of the genome.
We also present suggestive evidence for the existence of as many as
30 or more hotspots throughout the genome (Poisson distribution,
Supporting Information S1). With the exception of 2p16.3 (the
NRXN1 gene) we found approximately equal numbers in all
samples, and we present (below) indications from the published
literature that the hotspots are found in populations other than the
Quebec Founder Population; therefore their existence is probably
a universal phenomenon.
By filtering out frequently observed deletions, we eliminate from
consideration common deletions existing in the population (by
analogy with SNPs, probably those which arose a relatively long
time ago and against which there is no negative selection) as
well as those rare but recurring deletions arising between repeated
elements such as segmental duplications. In so doing, we maxi-
mized the chance of finding regions where deletions frequently
occur due to reasons other than the presence of repeated elements,
such as those in 16p11.2 associated with autism [7].
The hotspot in 20p12.1 is particularly noteworthy. A total of 27
independent deletions were documented in the 4 population
samples, 25 of which were seen only once. The exactitude of the
deletion borders is not in question, as the log R ratio graphs show
how cleanly the first and last SNP of each deletion could be called
(illustrated in Supporting Information S1). The instability of the
region is underlined by the detection of 3 de novo deletions within
the 440 ADHD children, one of which is adjacent to another
deletion inherited from the father (Figure 2).
Although this is to our knowledge the first such genome-wide
description of genomic instability at this level, our conclusions are
supported by published work in a variety of ways. First, deletions
in two of the genes residing in hotspots have been intensively
studied by many groups because of their roles in disease. Deletions
in the PARKIN gene (Chr6q26) are involved in about one-half of
familial early-onset Parkinson’s disease (PD) cases; as reviewed by
Hedrich et al. [8] exons 3 and/or 4 (corresponding to the hotspot
in 6q26) are deleted in 50% of cases, whereas exons 1 and 10,
farthest from the hotspot we identify, contribute less than 2% to
the total of exon deletion events. Similarly, more than 90% of the
66 deletions found in the 1.1 Mb NRXN1 region of Chromosome 2
by Rujescu et al. [9] cluster in the same 0.5 Mb where we have
identified deletions.
Second, in a genome-wide study similar to ours [10] several
hundred heterozygous deletions were detected in 810 individuals,
at about the same frequency as in the present study. When
recurring deletions were removed and the remainder analyzed for
clustering (our data-handling, not shown) patterns very similar to
ours are obtained, in almost exactly the same regions, especially in
20p12.1, 9p23 and 10q21.3 (6 or 7 independent deletions each).
Third, the DGV database (http://projects.tcag.ca/variation/;
UCSC Genome Browser) typically documents many deletions at
the hotspot sites we have identified. The inevitable imprecision in
mapping deletion endpoints when using the available CNV-calling
algorithms [11] makes it difficult to assess whether they represent
independent events, rather than simply the same common deletion
detected with variable apparent endpoints. Nevertheless it is
probable that the high frequency of detection of these events
reflects the hotspot nature of the genomic domain in at least some
instances. Finally, as discussed below, deletions are found in
primary tumors as well as tumor-derived cell lines in several of the
hotspots we define here, notably 20p12 [12], 6q26 [13] 10q21
[14].
It is of interest to place these findings in the context of what is
known regarding hotspots of chromatin instability, and deletions in
particular. One of the few such regions which are well enough
characterized to allow estimates of deletion frequency is in the
DMD gene, which at about 2.4 Mb is the longest known gene (this
was not formally included in our study since it is not autosomal).
The incidence of Duchenne muscular dystrophy is 1 per 3500
males and it is known that 1/3 of the cases are attributable to de
novo mutations, of which 60% are deletions [15]. A further 6% are
duplications, which we are not considering for this discussion.
Deletions arising in the major hotspot, involving introns 40–54
and covering 0.7 Mb (about the same as the length of our
hotspots), comprise about 2/3 of all those known in DMD. This
suggests a frequency of ascertainable de novo events of approxi-
mately 4610
25 per 0.7 Mb. A number of deletions presumably
occur in this region which do not affect exons, and have therefore
never been ascertained. Given that the median deletion length and
median intron length in this region are respectively about 60 kb
and 36 kb, we may project the total frequency of deletions which
lie entirely within introns as somewhat less than equal to the
frequency of ascertainable deletions which knock out an exon.
High Frequency Deletions
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8610
25 per generation per chromosome per 0.7 Mb in the
hotspot.
In our study, we observed 5 de novo deletions in a total of 13
hotspots covering about 7 Mb in 440 individuals. If representative,
this number reflects a rate of about 4610
24 per generation per
chromosome per 0.6 Mb (two parental chromosomes can
contribute to a deletion in autosomal loci). This is at least five
times more frequent than the major hotspot in DMD, and 2 or 3
orders of magnitude higher than the remaining 99.7% of the
genome, where only 2 de novo events were detected by us. (We
project this number to represent 4 events in total because of the
false negative call rate; see SI.) In the most active hotspot
(Chr20p12.1 where we found 3 de novo events), deletions occur at
about 10 times the rate seen even in intron 49 of the DMD gene,
where the greatest density of deletion clustering is seen. Therefore
we consider that at least some of the hotspots we describe are
considerably more unstable than any which have been quantita-
tively defined to date. Consistent with this is the detection of only
one deletion in the DMD gene hotspot in any of our 2540
individuals (exon 48 in an individual in the EN sample; results not
presented) or the 810 studied by Blauw et al. [10].
This work raises a number of intriguing questions at the
fundamental level, one being, why do these hotspots exist? It may
be that as a consequence of some form of stress, a chromatin loop
may escape its natural confines within the highly organized and
compact nuclear structure, and this event simply happens much
more often at these sites. Alternatively, these high-frequency
deletions may reflect some protective element, for which positive
selection has occurred. It is of note that these scenarios are not
mutually exclusive, in that there may exist situations of stress
where a chromatin domain may (or must) undergo deletion; it
would be to the organism’s advantage if the deletion occurred in a
DNA domain of low coding sequence density. In this way the
hotspots we have characterized could be considered as hypothet-
ical safety valves.
A second question that can be raised concerns the molecular
mechanism of the high frequency of deletions. Many of the
chromosomal elements such as low copy repeats (LCR), and
segmental duplications (SD) which have been associated with
structural alterations identified in diseases such as autism,
neurofibromatosis and Sotos syndrome (OMIM) have been ruled
out in the case of the DMD hotspot [15] and recently in the
chr6q26 hotspot [16]. Likewise, upon initial analysis we have
found no particular clustering of any of these with breakpoint
hotspots in our collection. Hotspots of recombination, invoked to
explain some deletion patterns, are spread across the genome at
intervals of ten to hundreds of kb (as visualized in the UCSC
Genome Browser), and although they may be the preferred site of
breakpoints when structural alterations in specific genes lead to an
identifiable phenotype, it is difficult to see how the presence of tens
of thousands of these sites may explain the existence of the handful
of deletion hotspots we have identified. Similarly, fragile sites
appear not to be associated in a significant way, in that only two
hotspot regions, 6q26 and 8p22 are in bands with fragile sites,
FRA6E and FRA8B respectively, based on the summary of 113
sites in about 310 bands by Calin et al. [17], and the latter
probably does not overlap the hotspot. The only finding which
may be pertinent to this discussion is the report of increased
incidence of double strand breaks in intron 49 in the DMD
hotspot when transfected into yeast [15]. This may reflect, for
example, increased TOPO2 activity, but at present we have no
evidence to implicate such activity in any of the regions in
question.
At a more applied level, these data also have implications for
gene-disease associations. The finding of rare deletions in or near
coding sequences, especially if they arise de novo in probands, has
often been accepted as de facto evidence that the affected gene may
be involved in the condition in question, simply because of the
expected low frequency of these events in the genome (examples
below). Our findings indicate that this argument does not hold for
deletions occurring in the hotspots we have documented, and since
Figure 2. Illumina Genome Viewer display of LogR ratios in the hotspot region of 20p12 in one trio. The offspring shows an inherited
deletion from the father, as well as a de novo deletion occurring adjacent to the former. The same SNP is circled in each panel.
doi:10.1371/journal.pone.0009401.g002
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indicates other hotspots exist, this is probably also true for a
number of other regions.
Nine of the documented hotspots carry genes, and every one has
been implicated in disease. We propose that a careful delineation
of precise deletion (or amplification) boundaries in and around
these genes will be useful, since at least some of the deletions may
be present simply due to the unstable nature of the chromosomal
domain rather than because they contributed to the phenotype by
affecting gene function. In our samples, exons were unaffected in
three of the nine genes, perhaps reflecting important roles for these
genes in human health; however because of small numbers
involved we cannot draw conclusions from this information.
Nevertheless, the patterns of exon disruption in the other genes are
somewhat informative, and the following paragraphs present some
examples.
NRXN1 and Autism
Deletions in this gene have been implicated in neurological
disorders including autism and mental retardation in anecdotal
fashion [1]–[4]. A major family study of autism [7], on the other
hand, found deletions which did not segregate with the condition,
and the authors concluded that there was no association. We
suggest that a close assessment of exon dosage in these families
may reveal either association, or the lack of it, between deleterious
deletions and autism. One may postulate that the majority of the
deletions in this region segregating in the families do not affect
coding sequence, and their presence reflects merely the hotspot
nature of the domain; those few which actually disrupt exons may
be shown to segregate with the condition. This scenario could be
predicted based on our results: 2 of 7 deletions in the SZ sample
affected coding regions of the gene, and one (de novo) deleted an
exon in an ADHD proband. None of the five deletions found in
other samples (EN, LG) affected exons. Similarly, a recent large
study assessing CNVs in NRXN1 in more than 35,000 individuals
[9] found CNVs in the SZ group at a frequency 3 times higher
than amongst controls, but in both patients and controls most
CNVs did not affect exons.
MACROD2 and Kabuki Syndrome
One report suggests this gene as a candidate for Kabuki
syndrome, since a de novo deletion involving exon 5 of this gene was
found in a proband [18]. Our finding of three individuals from
the EN cohort with deletions of exons 5 and/or 6 reduces the
likelihood of this proposed association being real, as a review of the
files of each of the 3 individuals showed no Kabuki-like symptoms
at all. The location of the gene in a hotspot of deletion greatly
increases the chance of sporadic exon deletions, and perhaps
explains the chance finding of the deletion in the Kabuki proband.
On the other hand, the incidence of exon-deleting mutations in
the EN cohort (3 out of 9) compared to 0 of about 16 in the other
cohorts suggests a possible involvement of this gene in EN.
This region of the genome has also been implicated in colorectal
cancer, with the report [12] that 23% of primary tumors and 55%
of cell lines had undergone deletion events with the consensus
minimum region of loss at 14.85–15.05 Mb, coinciding with the
hotspot we defined here. This group provided evidence that RNA
molecules encoded in the region may have tumour suppressor
activity, but it is also probable that the high frequency of deletions
may in part be attributable to the instability of the region.
CTNNA3 and Alzheimer’s Disease
The hotspot on chromosome 10 falls in the 39 half of this gene.
Exons were affected in a substantial proportion of the deletions,
including four such deletions which would produce a frameshift in
the LG cohort (all 4 subjects were mentally alert). This gene has
been associated with late-onset Alzheimer’s disease in women by
genetic studies [19]. The results reported here suggest that if
CTNNA3 is involved in Alzheimer’s it is not through a loss-of-
function mechanism.
PARK2/PARKIN and PD
The association of this gene with familial early-onset PD is well
established, since it is homozygously mutated in about 50% of such
cases [8]. The gene is mutated in a proportion of later-onset PD,
but it is currently uncertain whether single-copy deletions in fact
predispose to this condition. Our results may be pertinent in this
debate. Of the 2540 unrelated individuals in our studies, 22 (0.8%)
carry deletions in this gene; exons are affected by 10/15 of the
deletions in the ADHD, EN and SZ samples (virtually all of whom
are under the usual age of PD onset), but only by one of the 6
deletions in the LG sample, none of whom had PD in spite of
advanced age (p,0.05). These results are not inconsistent with a
role for PARKIN deletions in late onset PD and follow-up of
patients carrying deleterious deletions like those we have found
may help resolve this issue.
Cancer
One of the hallmarks of a tumor-suppressor gene (TSG) is the
presence of deletions in tumors which affect coding sequence, as
was seen with the prototypical TSG, RB1 [reviewed in 20]. If the
deletion is inherited, the classic pattern observed is the formation
of multiple tumors in the susceptible tissue, since each cell is in
principle predisposed to cancer. The search for deletions in tumors
has produced many TSG candidates, and some of the sites
frequently reported coincide with the hotspots described here. In
particular, a paradox has arisen in the case of the PARKIN gene
which our data may help resolve. This gene is described by some
groups as a TSG mainly on the strength of the frequency of exon-
disrupting deletions in cancer [13], [21] but patients with PD
appear to be, if anything, protected from most cancers [22]. In the
extreme situation of individuals inheriting two mutated alleles
(engendering early-onset Parkinson’s disease), one would expect
the appearance of multiple tumors, an observation which has not
been reported. However, if deletions occur at high frequency in
certain chromosomal sites in cancer merely as a consequence of
the unstable nature of the chromatin domain, their appearance
would not justify attributing tumor-suppressive function to the
gene product. Similar arguments apply to the very high frequency
of deletions in Chr20p21.1 in colorectal cancer, which overlap
between 14.85–15.05 Mb [12], in the most active hotspot we have
found. CTNNA3 [15] and TUSC3 [23], which have also been cited
as candidate TSGs for the same reason, could also have their
status as TSG re-evaluated in light of our results, given that for
each of these genes we have identified a number of cancer-free
adult individuals with exon-disrupting deletions (Table 1).
In general, therefore, the existence of hotspots with the
properties we present here should be incorporated into any
interpretation of deletion data concerning the genes associated
with these hotspots. In some instances, it may become appropriate
to incorporate exon-dosage assays in evaluating individuals’ risk
and potential treatment scenarios.
Methods
Ethical approval was obtained from Ethica, Montreal, for all
stages of recruitment and data generation [24] and all subjects
gave signed Informed Consent. Sample collection and phenotyp-
High Frequency Deletions
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described [24]. DNA was extracted from the buffy coats of blood
samples taken from donors and genotyped on Illumina Infinium
HumanHAP300 arrays (HumanHAP550 array in the case of the
longevity sample) according to the manufacturer’s instructions.
PennCNV [11] was run on the Illumina Beadstudio data
according to the creators’ instructions. For the ADHD sample,
after removal of incomplete trios and trios with high variance in
the log R ratios (generating more than 20 deletion calls by
PennCNV per individual; see Supporting Information S1), 440
trios were available for analysis. The results were processed as
described in the Supporting Information S1 to eliminate all but the
rare deletions (defined below).
Determining CNV boundaries with precision is a significant
issue in calling structural variations in the genome [11]; see also
Supporting Information S1. When the creators of PennCNV
tested the boundary precision by comparing inherited CNVs in
offspring with those in the parents [11] many were found to be
inaccurately called. We reasoned that combining PennCNV with
visual inspection of Beadstudio images might improve the
precision of CNV calls. Samples with a copy number of 1 at a
given SNP should show up as points of reduced but non-zero
normalized R value, hence below the main cluster as illustrated in
Figure 3b of [reference 24] and in the Supporting Information S1.
As discussed in Supporting Information S1, we chose a minimum
of 3 contiguous SNPs at low normalized R value as representing a
deletion event. Several deletions were selected for Syber Green
qPCR, with 100% concordance between called deletions and PCR
results (Supporting Information S1).
The ultimate goal of this work was to detect genomic dele-
tions potentially associated with disease, so we anticipated that
the pertinent alterations might be rare, as has been found for
schizophrenia (SZ) [2], [4]. Consequently we restricted our
evaluations to deletions occurring in only 1 or 2 individuals per
sample of about 500; in so doing, the complexity of the Beadstudio
clusters to be analyzed was reduced to a level at which visual
inspection became feasible (see Supporting Information S1).
Supporting Information
Supporting Information S1 Text, figures and tables presenting
information not shown in the main text.
Found at: doi:10.1371/journal.pone.0009401.s001 (3.61 MB
DOC)
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